Certara Announces New Release of Integral® Software
Latest version enhances efficiency, compliance, and user experience for PK scientists Radnor, PA. — December…
Danielle Pillsbury2025 年 12 月 16 日
Using M&S to Evaluate Oncology Drug Dosing
Learn how modeling & simulation improves oncology drug dosing, optimizing safety, efficacy, and personalized treatment…
Certara2025 年 11 月 14 日
ACoP 2025 Insights: Scaling the Future of QSP Modeling with Certara IQ™
At ACoP 2025, Certara showcased innovation with the launch of Certara IQ™ and Phoenix® Cloud,…
Certara2025 年 11 月 13 日
Seeing Across Species: Empiric Pharmacokinetic Time-Course Scaling in Phoenix®
Watch our on-demand webinar on empiric PK time-course scaling and learn how Certara’s translational experts…
Certara2025 年 11 月 13 日
Exposure–Response Analysis of Donidalorsen for the Treatment of Hereditary Angioedema
Certara and Ionis analyzed Phase 3 OASIS-HAE data showing flexible, effective donidalorsen dosing can reduce…
Certara2025 年 11 月 12 日
Supporting KalVista’s NDA Submission for a Novel HAE Treatment
To accelerate the first oral therapy for hereditary angioedema (HAE), KalVista Pharmaceuticals partnered with Certara…
Danielle Pillsbury2025 年 11 月 12 日
Supporting Ionis’ Donidalorsen BLA with Biomarker HAE Attack Rate Modeling
Discover how Certara applied exposure-response analysis and advanced modeling to optimize Donidalorsen dosing for hereditary…
Certara2025 年 11 月 10 日
Model-Informed Drug Development (MIDD) as a tool to Enhance Asset Value and Address Key Investor Concerns
Improve pediatric drug development with Certara’s Pediatric Practice, MIDD expertise for PIPs/PSPs, dose selection, regulatory…
Certara2025 年 11 月 10 日
Quantitative Model-Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation
This study demonstrates how model-informed approaches can improve dose selection decisions when direct clinical comparisons…
Certara2025 年 11 月 5 日
